Chahal h gliptins a new class of hypoglycemics

I think there may be a small mistake there!

Chahal is not a type of hypoglycemic, nor is gliptin a new class of hypoglycemics.

Gliptins are actually a class of medications that are used to treat type 2 diabetes. They are a type of incretin mimetic, which means they work by mimicking the action of incretin hormones, such as glucagon-like peptide-1 (GLP-1), that help regulate blood sugar levels.

Gliptins, such as sitagliptin (Januvia) and saxagliptin (Onglyza), are used to improve glycemic control in people with type 2 diabetes by increasing insulin secretion and reducing glucagon secretion. They are often used in combination with other medications, such as metformin, to help manage blood sugar levels.

Hypoglycemics, on the other hand, are medications that are used to treat hypoglycemia (low blood sugar). Examples of hypoglycemics include glucagon, which is used to treat severe hypoglycemia, and octreotide, which is used to treat hypoglycemia in people with insulinoma (a rare tumor of the pancreas).

So, while gliptins are an important class of medications for treating type 2 diabetes, they are not a type of hypoglycemic!